Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16212228 | 0.83 | HRH4 (0.47) | GAAKMT2AMEN1GLAHRH4 | |
| SCHEMBL1097561 | 0.83 | CHKA (0.52) | GAAKMT2AMEN1HRH4KDM4E | |
| SCHEMBL16965450 | 0.82 | JAK2 (0.56) | GAAKMT2AMEN1GLAADRA2C | |
| SCHEMBL5847761 | 0.81 | HRH4 (0.54) | GAAKMT2AMEN1HRH4KDM4E | |
| SCHEMBL6262576 | 0.81 | HRH4 (0.54) | GAAKMT2AMEN1HRH4KDM4E | |
| SCHEMBL2594167 | 0.81 | RAD52 (0.56) | GAAKMT2AMEN1GLAHRH4 | |
| SCHEMBL13027974 | 0.80 | HRH4 (0.61) | GAAKMT2AMEN1GLAHRH4 | |
| SCHEMBL21856960 | 0.79 | LNPEP (0.45) | GAAKMT2AMEN1GLAHRH4 | |
| SCHEMBL9877120 | 0.79 | ALDH1A1 (0.44) | GAAKMT2AMEN1HRH4KDM4E | |
| SCHEMBL10767289 | 0.79 | HRH4 (0.39) | GAAKMT2AMEN1GLAHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954251-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| EP-3048106-B1 | THIENOPYRIMIDINE AS INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2019-11-06 | — | — | EP | disclosed |
| US-20190106433-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | WINDTREE THERAPEUTICS, INC. | 2019-04-11 | — | — | US | disclosed |
| US-10183950-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-22 | — | — | US | disclosed |
| US-9938261-B2 | Heterocyclic compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170298022-A1 | Diamino-Pyridine, Pyrimidine, and Pyridazine Modulators of the Histamine H4 Receptor | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | US | disclosed |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| EP-2766359-B9 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES | AMBIT BIOSCIENCES CORP (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9604994-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-03-28 | — | — | US | disclosed |
| WO-2013078126-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013056070-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20130096113-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013034238-A1 | BENZONITRILE DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2013-03-14 | — | — | WO | disclosed |
| US-20100009987-A1 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | MERCK SHARP & DOHME LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100009987-A1 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | MERCK SHARP & DOHME LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100009987-A1 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | MERCK SHARP & DOHME LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| EP-2032138-A2 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | Merck Sharp & Dohme Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007141571-A2 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | MERCK SHARP & DOHME LIMITED (GB) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141571-A2 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | MERCK SHARP & DOHME LIMITED (GB) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096113-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FLT3, PDGFRB, PDGFRA | GAA 780/4885KMT2A 1053/4885MEN1 1498/4885 |
| US-10183950-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | PRKCQ, PRKDC, PRKACA | GAA 3362/4885KMT2A 1606/4885MEN1 3597/4885 |
| US-20170298022-A1 | Diamino-Pyridine, Pyrimidine, and Pyridazine Modulators of the Histamine H4 Receptor | HRH4, HRH3, HRH1 | GAA 4495/4885KMT2A 1207/4885MEN1 3316/4885 |
| US-20100009987-A1 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | MAPT, MARK4, MARK3 | GAA 1851/4885KMT2A 610/4885MEN1 4234/4885 |
| US-20190106433-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | PRKX, PRKCQ, PRKACA | GAA 2759/4885KMT2A 1428/4885MEN1 3225/4885 |
| US-10954251-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | PRKX, PRKCQ, PRKACA | GAA 2759/4885KMT2A 1428/4885MEN1 3225/4885 |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | PRKCQ, PRKDC, PRKACA | GAA 3362/4885KMT2A 1606/4885MEN1 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.